您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Brentuximab vedotin
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Brentuximab vedotin
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:914088-09-8
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议

产品名称
维布妥昔单抗;本妥昔单抗
产品介绍
Brentuximab vedotin (cAC10-vcMMAE) 是一种抗体-药物偶联物 (ADC),由抗CD30抗体和 Monomethyl auristatin E (MMAE) 组成。Brentuximab vedotin 抑制CD30阳性细胞,其IC50值为 2.5 ng/mL。Brentuximab vedotin 可用于复发难治性霍奇金淋巴瘤的研究。
生物活性

Brentuximab vedotin (cAC10-vcMMAE) is an antibody-drug conjugate(ADC)comprising an anti-CD30antibody and the cytotoxic agent MonomethylauristatinE (MMAE). Brentuximab vedotin inhibitsCD30-positive cells with anIC50of 2.5 ng/mL. Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma[1][2].

IC50& Target

IC50: 2.5 ng/mL (CD30)[2]

体外研究
(In Vitro)

Brentuximab vedotin (cAC10-vcMMAE) (1 μg/mL; 96 h) shows cytotoxicity to CD30+in Karpas 299 cells[2].
Brentuximab vedotin (CAC10-VCMMAE) (1 μg/mL; 12, 24 and 48 h) selectively induces growth arrest in G2/M phase then lead to apoptotic cell death[2].

Cell Cytotoxicity Assay[2]

Cell Line:Karpas 299 cells
Concentration:1 μg/mL
Incubation Time:96 h
Result:Showed cytotoxicity to CD30+Karpas 299 cells with an IC50value of 2.5 ng/mL.

Cell Cycle Analysis[2]

Cell Line:L540 cells
Concentration:1 μg/mL
Incubation Time:12, 24, and 48 h
Result:Selectively induced growth arrest in G2/M phase to apoptotic cell death.
体内研究
(In Vivo)

Brentuximab vedotin (cAC10-vcMMAE) (10-120 mg/kg; i.p. for 3 weeks) the maximum tolerated dose (MTD) is between 30 and 40 mg/kg[2].
Brentuximab vedotin (cAC10-vcMMAE) (0.3, 1 mg/kg; flanks injection; every 4 days for a total of 4 doses 1 mg/kg) induces tumor CD30 regression[2].

Animal Model:SCID mice[2]
Dosage:10 to 120 mg/kg
Administration:Intravenous injection; 10 to 120 mg/kg; for 3 weeks
Result:Showed an maximum tolerated dose between 30 and 40 mg/kg.
Animal Model:SCID mice[2]
Dosage:0.3 and 1 mg/kg
Administration:Flanks injection; 1 mg/kg every 4 days for a total of 4 doses; 0.3 mg/kg every 4 days for a total of 4 doses
Result:Induced complete and durable tumor regression, but 0.3 mg/kg provided lower therapy than 1 mg/kg dose.
Clinical Trial
性状

Solid

CAS 号

914088-09-8

中文名称

维布妥昔单抗;本妥昔单抗

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.